D-0623-2025 Class II Ongoing

Recalled by Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

FDA drug recall D-0623-2025 was initiated by Zydus Pharmaceuticals (USA) Inc on Aug 27, 2025 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity. The recall status is ongoing. Affected quantity: 270,125 Vials.

Recall details

Product Type
Drugs
Report Date
Sep 17, 2025
Initiation Date
Aug 27, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
270,125 Vials

Product description

Succinylcholine Chloride Injection, USP 200 mg/10 mL (20 mg/mL), Rx only, 10 mL Multiple-dose Vial, Sterile, Manufactured by Zydus Lifesciences Ltd, Vadodara, India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1377-1 (vial), NDC 70710-1377-2 (carton).

Reason for recall

Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.

Distribution pattern

MS, OH, LA, and Puerto Rico

Code information

Lot #s: L400077, exp: 8/31/2025; L400113, exp.: 9/30/2025; L400372, L400373, exp.: 3/31/2026; L400374, exp.: 4/30/2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0623-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0623-2025. Report a data issue: hello@regdatalab.com.